<!DOCTYPE html>
<!--[if lt IE 7 ]><html class="ie ie6" lang="en"> <![endif]-->
<!--[if IE 7 ]><html class="ie ie7" lang="en"> <![endif]-->
<!--[if IE 8 ]><html class="ie ie8" lang="en"> <![endif]-->
<!--[if (gte IE 9)|!(IE)]><!--><html lang="en"> <!--<![endif]-->
<head>

    <!-- Basic Page Needs
  ================================================== -->
	<meta charset="utf-8">
	<title>Times of Neurology</title>
	<meta name="description" content="Newsletter, Neurology,Epilepsy Designed by Medeka | medekahealth.com">
	<meta name="author" content="Neurology,Epilepsy">
	
    <!-- Mobile Specific Metas
  ================================================== -->
	<meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">
    
    <!-- CSS
  ================================================== -->
  	<link rel="stylesheet" href="css/zerogrid.css">
	<link rel="stylesheet" href="css/style.css">
    <link rel="stylesheet" href="css/responsive.css">
	<link rel="stylesheet" href="css/responsiveslides.css" />
	
	<!--[if lt IE 8]>
       <div style=' clear: both; text-align:center; position: relative;'>
         <a href="http://windows.microsoft.com/en-US/internet-explorer/products/ie/home?ocid=ie6_countdown_bannercode">
           <img src="http://storage.ie6countdown.com/assets/100/images/banners/warning_bar_0000_us.jpg" border="0" height="42" width="820" alt="You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today." />
        </a>
      </div>
    <![endif]-->
    <!--[if lt IE 9]>
		<script src="js/html5.js"></script>
		<script src="js/css3-mediaqueries.js"></script>
	<![endif]-->
	
	<link href='./images/ton.ico' rel='icon' type='image/x-icon'/>
    <script src="js/jquery.min.js"></script>
	<script src="js/responsiveslides.js"></script>
	<script>
		$(function () {
		  $("#slider").responsiveSlides({
			auto: true,
			pager: false,
			nav: true,
			speed: 500,
			maxwidth: 962,
			namespace: "centered-btns"
		  });
		});
	</script>
	
	
</head>
<body>
<!--------------Header--------------->
<header>
	<div class="subnav">
		<div class="wrap-subnav zerogrid">
			<div class="links">
				<ul>
					<li><a href="index.html">Home</a></li>
					<li><a href="aboutus.html">About</a></li>
					<li><a href="contact.html">Contact</a></li>
				</ul>
			</div>
		</div>
	</div>
	<div class="wrap-header zerogrid">
		<div id="logo"><a href="#"><img src="./images/logo.png"/></a></div>
</header>

<nav>
	<div class="wrap-nav zerogrid">
		<div class="menu">
	<ul>
		<li><a class="current" href="SV.html">Sodium Valproate</a></li>
		<li><a href="DP.html">Clobazam</a></li>
		<li><a href="OXCB.html">Oxcarbazepine</a></li>
        <li><a href="OXCB_PM.html">Pregabalin</a></li>
        <li><a href="NN.html">Neurology News</a></li>        
	</ul>
		</div>
		
		<div class="minimenu"><div>TOPICS</div>
			<select onchange="location=this.value">
            <option value="index.html">Home</option>
				<option value="SV.html">Sodium Valproate</option>
				<option value="DP.html">Clobazam</option>
           		<option value="OXCB_HM.html">Hospital Coverage </option>     
				<option value="OXCB.html">Oxcarbazepine</option>
                <option value="OXCB_PM.html">Pregabalin</option>
                <option value="EXPO.html">Disease Perspective</option>
                <option value="NN.html">Neurology News</option>
                <option value="quiz.html">Neurology Quiz</option>
			</select>
		</div>
	</div>
</nav>
<!--------------Content--------------->
<section id="content">
	<div class="wrap-content zerogrid">
	  <div class="row">
		  <div id="main-content" class="col-2-3">
            <div class="wrap-col">
					<article>
<h2h><a href="SV.html">Sodium Valproate</a></h2h>
                    <br>					 <ul><li>
					  <h2><a href="SVpage_2.html">Superior efficacy of sodium valproate IV for acute seizures and status epilepticus</a></h2>
						<span class="info">by medeka healthcare on october 01, 2013</a></span></li></ul>

			  </article>
					<article>
					  <h11>Sodium valproate IV in acute seizures and
status epilepticus: Clinical evidence</h11>
						<p>Several studies have reported that sodium valproate
IV is safe and effective in the management of status
epilepticus and acute repetitive seizures.<sup><a href="SV-VIII.html">2,3,6-9</a></sup></p>
                      <h11b>Sodium valproate IV is preferred over IV
phenytoin for status epilepticus<sup><a href="SV-VIII.html">3</a></sup></h11b>
                      <p>Chitsaz and colleagues reported that sodium valproate
IV is more effective and should be preferred over
IV phenytoin in status epilepticus treatment. In this
study, patients were randomly assigned to treatment
with either sodium valproate IV or phenytoin IV.
The rate of response to treatment within the first
12 h showed no significant differences between
treatment with sodium valproate IV and phenytoin
IV (73.3 <i>vs.</i> 60%, p=0.06). No clinical complications
were observed in the sodium valproate IV group;
whereas in the phenytoin group, 4 patients (26.7%)
had complications because of side effects (p=0.03).
No difference in terms of adverse events was
found (p=0.06).<sup><a href="SV-VIII.html">3</a></sup></p><img src="images/blog03.gif"/>
                      <h11b>Sodium valproate IV is easy to use and better
tolerated than IV phenytoin<sup><a href="SV-VIII.html">6</a></sup></h11b>
                       <p>Agarwal and colleagues reported that sodium
valproate IV is comparably effective, better tolerated,
and easy to use than phenytoin IV in patients with
benzodiazepine refractory status epilepticus.<sup><a href="SV-VIII.html">6 </a></sup>The
patients (n=100) were randomly divided into 2 groups
(n=50 each) and received either sodium valproate IV
or phenytoin IV. The treatment was considered to be
successful if it caused cessation of seizures within
20 minutes after infusion with no seizures for the next
12 hours. Results of the study were as follows:</p>
                       <ul>
                            <li>Sodium valproate IV was as effective as phenytoin
IV in patients with status epilepticus (88 <i><i>vs.</i></i> 84%,
p>0.05; Figure 1).</li><img src="images/figure_04.gif"/>
                            <li>Patients who had status epilepticus for a duration
of <2 hours showed significant response with
sodium valproate IV and phenytoin IV (Figure 1).</li>
                            <li>Total number of adverse events did not differ
significantly between the two groups (p>0.05).</li> 
 <li>No differences were observed among the
treatments with respect to recurrence after the
12-hour study period or the outcome at 7 days.</li>
                      </ul>
                      <p>Agarwal et al. concluded that sodium valproate
IV might be used as an alternative to phenytoin
in patients with benzodiazepine refractory status
epilepticus, especially among those with cardiorespiratory
disease.<sup><a href="SV-VIII.html">6</a></sup></p>
                      <p>Gilad and colleagues substantiated that sodium
valproate IV was better tolerated and had comparable
efficacy to IV phenytoin for the treatment of status
epilepticus and acute repetitive seizures.<sup><a href="SV-VIII.html">7</a></sup> Patients
were treated either with sodium valproate IV (n=49)
or IV phenytoin (n=25). Both drugs had comparable
seizure discontinuation (88% <i>vs.</i> 87.8%). No side
effects were observed in the sodium valproate IV
group, whereas 12% patients in the phenytoin group
showed incidences of adverse events.<sup><a href="SV-VIII.html">7</a></sup></p><img src="images/blog04.gif"/>
<h11b>Sodium valproate IV is effective and better
tolerated than phenytoin by patients with
generalized convulsive status epilepticus<sup><a href="SV-VIII.html">8</a></sup></h11b><p>In a systematic review, Brigo and colleagues reported
that IV valproic acid has better tolerability than
phenytoin in generalized convulsive status epilepticus
without any statistically significant differences in
terms of efficacy. Clinical seizure cessation after
drug administration, seizure freedom at 24 hours,
and adverse effects were determined. As compared to
phenytoin, sodium valproate IV had statistically lower
risk of adverse effects with no differences in cessation
of generalized convulsive status epilepticus after
drug administration and seizure freedom at 24 hours
(Table 1).<sup><a href="SV-VIII.html">8</a></sup></p><img src="images/Table_03.gif"/>

<h11b>Sodium valproate IV is more effective and
safe in children than IV phenobarbital<sup><a href="SV-VIII.html">2</a></sup></h11b>

<p>Malamiri et al. reported that rapid loading of sodium
valproate IV is effective, safe, and should be
recommended over IV phenobarbital in children
with status epilepticus and acute prolonged convulsive
seizures.<sup><a href="SV-VIII.html">2</a></sup> They compared the efficacy and safety of
both drugs in patients. In this study, children with
status epilepticus received either phenobarbital IV
(n=30) or sodium valproate IV (n=30) randomly. Rapid
infusion of sodium valproate IV was more successful
for seizure termination (within 20 min after infusion)
in the patients (90% <i>vs.</i> 77%, p=0.189). Occurrence
of clinically significant adverse events was less in
the sodium valproate IV group as compared to the
phenobarbital group (24 <i>vs.</i> 74%, p<0.001).<sup><a href="SV-VIII.html">2</a></sup></p>


<h11b>Sodium valproate IV is more effective than
levetiracetam or phenytoin IV<sup><a href="SV-VIII.html">9</a></sup></h11b>

<p>According to a study by Alvarez and colleagues,
sodium valproate IV is more effective than
levetiracetam and phenytoin IV.<sup><a href="SV-VIII.html">9</a></sup> They performed
a comparative study with phenytoin IV, sodium
valproate IV, and levetiracetam IV in status
epilepticus patients. In this retrospective study, data
of 187 patients were considered, in which phenytoin,
sodium valproate IV, or levetiracetam was given
after the administration of benzodiazepines. The
parameters assessed were: clinical status epilepticus
features, failure of second-line treatment to control
status epilepticus, new handicap, and mortality at
hospital discharge. The findings of the study were:<ul>
                            <li>Failure rate to control status epilepticus episodes,
their severity, and the frequency of drug-related
Sodium valproate IV allows rapid loading in
patients with inadequate seizure control and easy
transition from IV to oral route.
Superior efficacy of sodium
valproate IV reported in acute
seizures and status epilepticus
Times of Neurology TIMES OF NEUROLOGY 5PG
mortality were least in the case of sodium valproate
IV as compared to the other two drugs.</li>
                            <li>Levetiracetam failed to control status epilepticus
more often than sodium valproate IV (odds
ratio: 2.69; 95% confidence interval: 1.19–6.08).<sup><a href="SV-VIII.html">9</a></sup></li>
                      </ul></p>

</article>
					<ul id="pagi">
						<li><a  href="SV-V.html">1</a></li>
						<li><a class="current" href="SV-VI.html">2</a></li>
                        <li><a href="SV-VII.html">3</a></li>
                        <li><a href="SV-VIII.html">4</a></li>
					</ul>
					
		    </div>
<p><br>
            <div class="featured">
	<div class="wrap-col">
		<div class="slider">
			<div class="rslides_container">
				<ul class="rslides" id="slider">
					<li><img src="images/slide03.jpg"/></li>
					<li><img src="images/slide15.jpg"/></li>
                  
				</ul>
			</div>
		</div>
	</div>
</div>            
            
	    </div>
			<div id="sidebar" class="col-1-3">
				<div class="wrap-col">
                <div class="box">
					  <div class="heading">
					    <h2>Contents</h2></div>
						<div class="content">
							<div class="linklist">
							  <ul><li><a href="IM.html">Initial monotherapy with levetiracetam fails more
frequently than monotherapy with valproate or
oxcarbazepine:</a>An enlightening evidence</li>
									<li><a href="SVpage_1.html">Sodium valproate:</a>A gold standard for the treatment of
childhood epilepsy</li>
									<li><a href="SVpage_2.html">Superior efficacy of sodium valproate IV reported in</a> acute seizures and status epilepticus</li>
									<li><a href="DP.html">Clobazam: </a>An effective long-term treatment option
for Lennox-Gastaut syndrome</li>
                                    <li><a href="OXCB_HM.html">Hospital coverage:</a>Krishna Institute of Medical Sciences</li>
                                <li><a href="OXCB.html">Oxcarbazepine:</a>A valuable treatment option for
partial-onset seizures in children</li>
                                      <li><a href="OXCB_PM.html">Pregabalin and methylcobalamin combination for
neuropathic pain:</a>The Indian scenario</li>
                                <li><a href="EXPO.html">Important aspects of epilepsy management:</a>during pregnancy</li>
                                    <li><a href="NN.html">Neurology News</a></li>
                                    <li><a href="quiz.html">Neurology Quiz</a></li>
                                    
								</ul>
							</div>
						</div>
				  </div>
                  <div class="box">
						<div class="heading"><h2>News Digest</h2></div>
						<div class="content">
							<div class="posts">
								<img src="images/post01.png"/>
								<h4><a href="#">ECG should be considered
in patients with refractory
epilepsy</a></h4><br>
									<p>Analysis of electrocardiogram
(ECG) monitoring
in patients with refractory
epilepsy revealed significant differences in
heart rate between ictal and pre-ictal states,
between ictal and post-ictal states, and
between pre- and post-ictal states. Hence,
ECG might be helpful to detect serious
cardiac abnormalities in patients with
refractory epilepsy.</p><p class="sideref">J Res Med Sci. 2013;18(Suppl 1):S32–4.</p>
							</div>
							<div class="posts">
								<img src="images/post02.png"/>
								<h4><a href="#">Use of gabapentin in pregnancy is not associated with increased risk of major malformations</a></h4><br>
							<p>A prospective study of
pregnancy outcomes in
223 pregnant women who were exposed to gabapentin and 223 pregnant women who were unexposed to gabapentin reported
that gabapentin use in pregnancy was not associated with increased risk for major malformations.</p> <p class="sideref">Epilepsy Behav. 2013;26(1):109–13.</p>
							</div>
							<div class="posts">
								<img src="images/post03.png"/>
								<h4><a href="#">A portable automatic device for the detection of generalized tonicclonic seizures</a></h4>
							<p>Increased S100B protein levels in cerebrospinal fluid may be associated with the neuronal damage following central nervous infections.</p>
							<p class="sideref">Epilepsia. 2013;54(4):e58–61.</p></div>
						</div>
				  </div>
					<div class="box">
						<div class="heading">
						  <h2>Updates</h2></div>
						<div class="content"> <img src="images/updates_add01.gif"/>						  <img src="images/updates_add02.gif"/>
						</div>
					</div>
				</div>
			</div>
	  </div>
  </div>
</section>
<!--------------Footer--------------->
<footer>
	<div class="copyright">
		<p>Copyright © 2013 Medekahealth.com - All rights reserved. | Design: <a href="http://www.medekahealth.com/">MedekaHealth.com</a><a href=</p>
	</div>
</footer>

</body></html>